Paul Hastings Advises J.P. Morgan, Jefferies, Citigroup and TD Cowen in Vor Biopharma’s Underwritten Public Offering
Paul Hastings LLP advised J.P. Morgan, Jefferies, Citigroup and TD Cowen as joint book-running managers in Vor Biopharma’s (Nasdaq: VOR) underwritten public offering of 10 million shares of its common stock, with gross proceeds expected to be $100 million. The offering is expected to close on or about Nov. 12, 2025, subject to customary closing conditions.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi led the Paul Hastings team, which included of counsel Ryan Brewer and associates Michelle Sidle and Adam Swank.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.